Sonoma Pharmaceuticals Files Q3 2025 10-Q

TL;DR

Sonoma Pharma (SNN) filed their Q3 10-Q, covering results up to Dec 31, 2024. Details to follow.

AI Summary

Sonoma Pharmaceuticals, Inc. filed its 10-Q for the period ending December 31, 2024. The company, formerly known as Oculus Innovative Sciences, Inc., is in the surgical and medical instruments sector. The filing covers the third quarter of their fiscal year, which ends on March 31, 2025. Specific financial details for the quarter and year-to-date are not provided in this header information.

Why It Matters

This filing provides investors with an update on Sonoma Pharmaceuticals' financial performance and operational status for the third quarter of their fiscal year.

Risk Assessment

Risk Level: medium — As a publicly traded company in the medical device sector, Sonoma Pharmaceuticals faces inherent risks related to market competition, regulatory approvals, and financial performance.

Key Numbers

• 2024-12-31 — Period End Date (The 10-Q covers financial information up to this date.)
• 2025-02-05 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
• 0331 — Fiscal Year End (Indicates the company's fiscal year concludes on March 31st.)

Key Players & Entities

• Sonoma Pharmaceuticals, Inc. (company) — Filer
• Oculus Innovative Sciences, Inc. (company) — Former company name
• 2024-12-31 (date) — Period of report
• 2025-02-05 (date) — Filing date
• 3841 (number) — Standard Industrial Classification (SIC) code for Surgical & Medical Instruments & Apparatus

FAQ

Key Financial Figures

• $0.0001 — nge on Which Registered Common Stock, $0.0001 par value SNOA The Nasdaq Stock Marke

Filing Documents

• sonoma_i10q-123124.htm (10-Q) — 761KB
• sonoma_ex3101.htm (EX-31.1) — 8KB
• sonoma_ex3102.htm (EX-31.2) — 9KB
• sonoma_ex3201.htm (EX-32.1) — 5KB
• 0001683168-25-000736.txt ( ) — 3865KB
• snoa-20241231.xsd (EX-101.SCH) — 27KB
• snoa-20241231_cal.xml (EX-101.CAL) — 49KB
• snoa-20241231_def.xml (EX-101.DEF) — 88KB
• snoa-20241231_lab.xml (EX-101.LAB) — 276KB
• snoa-20241231_pre.xml (EX-101.PRE) — 222KB
• sonoma_i10q-123124_htm.xml (XML) — 475KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1. Unaudited Financial Statements 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Comprehensive Loss 4 Condensed Consolidated Statements of Cash Flows 5 Condensed Consolidated Statements of Changes in Stockholders' Equity 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 29

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32 Item 3. Defaults Upon Senior Securities 32 Item 4. Mine Safety Disclosures (Not applicable.) 32 Item 5. Other Information 32 Item 6. Exhibits 33

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements SONOMA PHARMACEUTICALS, INC. AND SUBSIDIARIES Condensed Consolidated Balance Sheets (In thousands, except share amounts) December 31, 2024 March 31, 2024 (Unaudited) ASSETS Current assets: Cash and cash equivalents $ 5,236 $ 3,128 Accounts receivable, net 2,405 2,898 Inventories, net 3,143 2,719 Prepaid expenses and other current assets 1,387 3,541 Current portion of deferred consideration, net of discount 209 262 Total current assets 12,380 12,548 Property and equipment, net 215 365 Operating lease, right of use assets 119 286 Deferred tax asset 760 1,145 Deferred consideration, net of discount, less current portion 121 330 Other assets 73 66 Total assets $ 13,668 $ 14,740 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 1,395 $ 607 Accrued expenses and other current liabilities 1,916 2,113 Deferred revenue, current portion 302 478 Short-term debt – 323 Operating lease liabilities, current portion 90 198 Total current liabilities 3,703 3,719 Deferred revenue, net of current portion 30 87 Withholding tax payable 5,036 4,710 Operating lease liabilities, less current portion 29 87 Total liabilities 8,798 8,603 Commitments and Contingencies (Note 5) – Stockholders' Equity: Preferred stock, $ 0.0001 par value; 714,286 shares authorized at December 31, 2024 and March 31, 2024, no shares issued and outstanding at December 31, 2024 and March 31, 2024 – – Common stock, $ 0.0001 par value; 50,000,000 and 24,000,000 shares authorized at December 31, 2024 and March 31, 2024, respectively, 1,615,765 and 780,371 shares issued and outstanding at December 31, 2024 and March 31, 2024, respectively (Note 1) (Note 7) – – Additional paid-in capital 206,454 203,209 Accumulated deficit ( 197,030 ) ( 194,349 ) Accumulated other comprehensive loss ( 4,554 ) ( 2,723 ) Total stockholders' equity 4,870 6,1

View Full Filing

View this 10-Q filing on SEC EDGAR